Download PDF
CC BY 4.0 · Surg J (N Y) 2020; 06(02): e112-e117
DOI: 10.1055/s-0040-1710530
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Multimodality Management of Ruptured Large Hepatocellular Carcinoma and Its Recurrence: Rupture at Presentation Should Not Rupture Hope of Long-Term Survival

Gunjan S. Desai
1   Department of Surgical Gastroenterology, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India
,
Prasad M. Pande
1   Department of Surgical Gastroenterology, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India
,
Rajvilas A. Narkhede
2   Department of Surgical Gastroenterology, Dr. Balabhai Nanavati Superspeciality Hospital, Mumbai, Maharashtra, India
,
Prasad K. Wagle
2   Department of Surgical Gastroenterology, Dr. Balabhai Nanavati Superspeciality Hospital, Mumbai, Maharashtra, India
› Author Affiliations
Further Information

Publication History

04 August 2019

17 March 2020

Publication Date:
16 June 2020 (online)

   Permissions and Reprints

Abstract

A 59-year-old gentleman with a history of aortic valve replacement presented with spontaneously ruptured hepatocellular carcinoma in right lobe of a hepatitis C virus (HCV)-related chronic liver disease with hemoperitoneum. This acute emergency was managed by transarterial embolization. Right trisectionectomy with preservation of segment IVB after augmentation of future liver remnant by transarterial chemoembolization followed by portal vein embolization was subsequently performed. Sustained virological response to HCV was attained after surgery using sofosbuvir-based regimen. He had a delayed operative bed recurrence 1.5 years later with pulmonary metastatic disease which was managed by operative bed metastasectomy with mesh reconstruction of diaphragm and sorafenib. He is on sorafenib since past 3 years and doing well at 4.5-years follow-up since the first presentation, with significant regression of pulmonary disease and no other disease elsewhere, which highlights that where there is hope, there is a way.

Keywords

sorafenib - hepatocellular carcinoma - trisectionectomy - portal vein embolization

Ethics Statement

The study was performed after the approval of research protocols by the Ethics Committee of Lilavati Hospital and Research Centre in accordance with international agreements (World Medical Association Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Subjects,” amended in October 2013, www.wma.net).


Informed Consent

Written informed consent was obtained from the patient involved in the study.


Author Contributions

G.S.D. performed critical revision of the manuscript for intellectual content, technical support, material support, and study supervision. P.M.P. was responsible for collecting data, analysis of data, preparing the initial draft of the manuscript, and critical revision of the manuscript for intellectual content. R.A.N. performed critical revision of the manuscript for intellectual content, technical support, material support, and study supervision. P.K.W. studied concept, did critical revision of the manuscript for intellectual content, administrative support, technical support, material support, and study supervision.


Financial Disclosure

The authors declare that this study has received no financial support.


 

  • References

  • 1 Rabie M, Alqahtani S, El Hakeem I. , et al. Ruptured hepatocellular carcinoma: management options. Saudi Surg J 2017; 5 (01) 27-34
    CrossrefPubMedGoogle Scholar
  • 2 Aoki T, Kokudo N, Matsuyama Y. , et al; Liver Cancer Study Group of Japan. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg 2014; 259 (03) 532-542
    CrossrefPubMedGoogle Scholar
  • 3 Zhong F, Cheng XS, He K, Sun SB, Zhou J, Chen HM. Treatment outcomes of spontaneous rupture of hepatocellular carcinoma with hemorrhagic shock: a multicenter study. Springerplus 2016; 5 (01) 1101
    CrossrefPubMedGoogle Scholar
  • 4 Darnis B, Rode A, Mohkam K, Ducerf C, Mabrut JY. Management of bleeding liver tumors. J Visc Surg 2014; 151 (05) 365-375
    CrossrefPubMedGoogle Scholar
  • 5 Bassi N, Caratozzolo E, Bonariol L. , et al. Management of ruptured hepatocellular carcinoma: implications for therapy. World J Gastroenterol 2010; 16 (10) 1221-1225
    CrossrefPubMedGoogle Scholar
  • 6 Gloor S, Jensen KO, Breitenstein S, Binkert CA, Angst E, Hetzer FH. Acute abdomen: a rare case of ruptured hepatocellular carcinoma. Case Rep Gastroenterol 2017; 11 (01) 155-161
    CrossrefPubMedGoogle Scholar
  • 7 Moris D, Chakedis J, Sun SH. , et al. Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review. J Surg Oncol 2018; 117 (03) 341-353
    CrossrefPubMedGoogle Scholar
  • 8 Zhu Q, Qiao G, Xu C. , et al. Conditional survival in patients with spontaneous tumor rupture of hepatocellular carcinoma after partial hepatectomy: a propensity score matching analysis. HPB (Oxford) 2019; 21 (06) 722-730
    CrossrefPubMedGoogle Scholar
  • 9 Joliat GR, Labgaa I, Uldry E, Demartines N, Halkic N. Recurrence rate and overall survival of operated ruptured hepatocellular carcinomas. Eur J Gastroenterol Hepatol 2018; 30 (07) 792-796
    CrossrefPubMedGoogle Scholar
  • 10 Lee HS, Choi GH, Choi JS. , et al. Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea. Ann Surg Treat Res 2019; 96 (06) 275-282
    CrossrefPubMedGoogle Scholar
  • 11 Schwarz L, Bubenheim M, Zemour J. , et al; FRENCH association. Bleeding recurrence and mortality following interventional management of spontaneous HCC Rupture: results of a Multicenter European Study. World J Surg 2018; 42 (01) 225-232
    CrossrefPubMedGoogle Scholar
  • 12 Tanaka S, Kaibori M, Ueno M. , et al. Surgical outcomes for the ruptured hepatocellular carcinoma: multicenter analysis with a case-controlled study. J Gastrointest Surg 2016; 20 (12) 2021-2034
    CrossrefPubMedGoogle Scholar
  • 13 Ou D, Yang H, Zeng Z, Luo Y, Yang L. Comparison of the prognostic influence of emergency hepatectomy and staged hepatectomy in patients with ruptured hepatocellular carcinoma. Dig Liver Dis 2016; 48 (08) 934-939
    CrossrefPubMedGoogle Scholar
  • 14 Sada H, Ohira M, Kobayashi T, Tashiro H, Chayama K, Ohdan H. An analysis of surgical treatment for the spontaneous rupture of hepatocellular carcinoma. Dig Surg 2016; 33 (01) 43-50
    CrossrefPubMedGoogle Scholar
  • 15 Lee HS, Choi GH, Kang DR. , et al. Impact of spontaneous hepatocellular carcinoma rupture on recurrence pattern and long-term surgical outcomes after partial hepatectomy. World J Surg 2014; 38 (08) 2070-2078
    CrossrefPubMedGoogle Scholar
  • 16 She WH, Chok KSh. Strategies to increase the resectability of hepatocellular carcinoma. World J Hepatol 2015; 7 (18) 2147-2154
    CrossrefPubMedGoogle Scholar
  • 17 Li J, Ewald F, Gulati A, Nashan B. Associating liver partition and portal vein ligation for staged hepatectomy: from technical evolution to oncological benefit. World J Gastrointest Surg 2016; 8 (02) 124-133
    CrossrefPubMedGoogle Scholar
  • 18 Alizai PH, Haelsig A, Bruners P. , et al. Impact of liver volume and liver function on posthepatectomy liver failure after portal vein embolization—a multivariable cohort analysis. Ann Med Surg (Lond) 2017; 25: 6-11
    PubMedGoogle Scholar
  • 19 Ronot M, Cauchy F, Gregoli B. , et al. Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. HPB (Oxford) 2016; 18 (08) 684-690
    CrossrefPubMedGoogle Scholar
  • 20 Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006; 93 (09) 1091-1098
    CrossrefPubMedGoogle Scholar
  • 21 Morisco F, Granata R, Stroffolini T. , et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19 (18) 2793-2798
    CrossrefPubMedGoogle Scholar
  • 22 Reig M, Mariño Z, Perelló C. , et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65 (04) 719-726
    CrossrefPubMedGoogle Scholar
  • 23 Waziry R, Hajarizadeh B, Grebely J. , et al. No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017; 66 (01) S12
    PubMedGoogle Scholar
  • 24 Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F. ; Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows. World J Gastroenterol 2018; 24 (24) 2582-2595
    CrossrefPubMedGoogle Scholar
  • 25 Russo F, Tessari M, Imondi A, Lynch E, Farinati F. HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: still an issue?. Hepatoma Res 2018; 4 (06) 25-38
    CrossrefPubMedGoogle Scholar
  • 26 Llovet JM, Ricci S, Mazzaferro V. , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
    CrossrefPubMedGoogle Scholar
  • 27 Cheng AL, Kang YK, Chen Z. , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34
    CrossrefPubMedGoogle Scholar
  • 28 Bruix J, Takayama T, Mazzaferro V. , et al; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16 (13) 1344-1354
    CrossrefPubMedGoogle Scholar
  • 29 Sacco R, Granito A, Bargellini I. , et al. Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. Future Oncol 2018; 14 (29) 3049-3058
    CrossrefPubMedGoogle Scholar
  • 30 Lee HW, Kim HS, Kim SU. , et al. Survival estimates after stopping sorafenib in patients with hepatocellular carcinoma: NEXT score development and validation. Gut Liver 2017; 11 (05) 693-701
    CrossrefPubMedGoogle Scholar
  • 31 Marrero JA, Kudo M, Venook AP. , et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol 2016; 65 (06) 1140-1147
    CrossrefPubMedGoogle Scholar